ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0946

The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE

Catherine Sims1, Amanda Eudy2, Jayanth Doss1, Lisa Criscione-Schreiber3, Kai Sun3, Rebecca Sadun1, Jennifer L Rogers4 and Megan Clowse1, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University School of Medicine, Durham, NC, 4Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC

Meeting: ACR Convergence 2022

Keywords: pregnancy, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The ACR Reproductive Health Guidelines recommend that a woman conceive when her SLE is quiescent, she is not taking a teratogenic medication, and that she should continue pregnancy-compatible medications, such as HCQ and AZA, to control SLE activity throughout pregnancy. Assisting women with SLE in achieving this well-planned pregnancy, however, is an unmet challenge. We created the HOP-STEP Intervention to ascertain pregnancy interest and contraceptive use, followed by a personalized pregnancy prevention or planning discussion between the rheumatologist and patient with a Discussion Guide. Here we report the medical readiness and pregnancy outcomes among women who received the HOP-STEP Intervention.

Methods: All adult female participants were enrolled in a prospective SLE registry, met SLICC or 1997 ACR criteria for SLE. On an intake form for each clinic visit, women answered 1) “Would you or your partner like to get pregnant in the next 12 months?” and 2) contraceptive use. Women were defined as ‘not medically ready for pregnancy’ if they were taking a teratogen, had proteinuria ≥ 500 mg, or had a physician’s global assessment of ≥ 1.5 at the visit. Women who did not complete the survey were excluded from analysis. ‘Ill-timed’ pregnancies were defined as those conceived when the woman did not intend pregnancy or she was ‘not medically ready’ for pregnancy. Participants were followed for 14-52 months, depending on enrollment date, for pregnancy outcomes.

Results: A total of 42 women in the registry reported an interest in pregnancy with 40 of these women having documentation of a HOP-STEP pregnancy planning discussion. Of these, 16 women conceived 20 pregnancies. Among the 13 well-timed pregnancies, the rates of pregnancy loss (30%) and preterm birth (33% of live births) was high, though none were related to SLE activity or medications (Table 1). Another 3 conceived when not medically-ready for pregnancy due to active SLE and/or mycophenolate (MMF) use. These women had a plan to delay conception using condoms & spermicide but were not interested in more effective contraception due to their strong desire for pregnancy. Two women were interested in pregnancy and not using contraception, but the provider did not have a HOP-STEP pregnancy planning discussion; both of these women conceived while taking MMF. An additional 2 women conceived after reporting they did not intend on pregnancy and were not using contraception. Both had a HOP-STEP contraception discussion with a plan to receive highly effective contraception at the time of conception. Among the ill-timed pregnancies, the rates of pregnancy loss (28%) and preterm birth (40% of live births) was similarly high, though these complications were likely related to teratogen use and/or SLE activity.

Conclusion: Well-timed pregnancies in women with SLE have fewer complications related to teratogen use and SLE activity compared to ill-timed pregnancies. This study highlights the importance of addressing pregnancy planning and contraception in all women at every clinic visit. The HOP-STEP Intervention, when fully implemented, can promote well-timed pregnancies with improved outcomes.

Supporting image 1

Table 1: Pregnancy outcomes based on pre-pregnancy discussion within at DLR clinic visit and whether the woman was ‘medically ready’ for pregnancy at conception. Given the small number of pregnancies within each category of pregnancy planning, statistical assessments cannot be made.


Disclosures: C. Sims, None; A. Eudy, GlaxoSmithKlein(GSK), Pfizer, Exagen; J. Doss, Pfizer; L. Criscione-Schreiber, GlaxoSmithKlein(GSK); K. Sun, None; R. Sadun, None; J. Rogers, None; M. Clowse, Exagen.

To cite this abstract in AMA style:

Sims C, Eudy A, Doss J, Criscione-Schreiber L, Sun K, Sadun R, Rogers J, Clowse M. The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-pregnancy-planning-and-medical-readiness-on-reproductive-outcomes-in-women-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-pregnancy-planning-and-medical-readiness-on-reproductive-outcomes-in-women-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology